pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,180 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1772Endpoints1382Fierce Biotech700BioSpace694BioPharma Dive522raps231onclive165fda recalls111
therapy area
allOncology12282Rare Disease3188Immunology2860Cardiology2725Hematology2166Pulmonology2136Vaccines
  • BioNTech appoints Sobi head Guido Oelkers as new CEO to steer oncology shift
    BioNTech announced that Guido Oelkers, who has led the rare‑disease focused Swedish company Sobi since 2017, will become its next chief executive officer. Oelkers is slated to take over the role b…
    BioPharma Dive · 3mo agoNeutral↗ source
  • Supernus and Individor to merge, creating $2 billion brain-drug company
    Supernus and Individor announced a merger that will combine their portfolios of neurological medicines. The two firms together generated about $2 billion in revenue in 2025 from roughly a dozen CN…
    BioPharma Dive · 3mo agoDealPositive↗ source
← prev
page 45 of 88
next →
fda medwatch109
globenewswire health73
fda press59
1794
Psychiatry & CNS1200
Ophthalmology1049
Endocrinology & Metabolism775
Pain773
Nephrology759
  • Supernus and Indivior announce all-stock merger to create CNS-focused drugmaker
    Supernus Pharmaceuticals and Indivior Pharmaceuticals have signed an all‑stock merger agreement to combine their businesses. The new company will be dedicated to developing treatments for central…
    Endpoints · 3mo agoDealPositive↗ source
  • Dash Bio secures $30 million Series A funding led by Oak HC/FT
    Dash Bio announced it has closed a $30 million Series A financing round, with Oak HC/FT serving as the lead investor. The capital will be used to expand the company’s platform that offers cloud‑sty…
    Endpoints · 3mo agoDealPositive↗ source
  • Amgen reports hackers stole patient and company data in cloud breach
    Amgen disclosed on Friday that hackers have accessed and taken both company and patient information in a cyber-attack. The company said the intrusion was detected as "unauthorized activity" affect…
    Endpoints · 3mo agoNegative↗ source
  • China's biotech surge highlights work-life tension for industry leaders
    China's biotechnology sector is accelerating, prompting discussions about the demanding work culture among its leaders. Shefali Agarwal, the US‑based chief executive of Sironax, said she works lon…
    Endpoints · 3mo agoNeutral↗ source
  • BioNTech appoints Sobi's Guido Oelkers as new CEO, to start by Feb 1 2027
    BioNTech announced that Guido Oelkers, currently a leader at Swedish biotech company Sobi, will become its next chief executive officer. Oelkers is expected to take over the role no later than Feb…
    Endpoints · 3mo agoNeutral↗ source
  • HHS Secretary RFK Jr. defends Trump admin, critiques vaccine research while endorsing measles vaccine
    HHS Secretary Robert F. Kennedy Jr. gave an interview on August 3, 2026 in which he reiterated his support for the Trump administration and voiced criticism of current vaccine research practices.…
    Endpoints · 3mo agoNeutral↗ source
  • Boticelli Foods recalls Bettergoods pistachio nut butter over possible Salmonella contamination
    Boticelli Foods of Melville, New York announced a recall of one lot of Bettergoods Pistachio Nut Butter, a 6.7‑oz (190 g) product identified by UPC 194346207961 and lot number LB028ACP04. The reca…
    fda recalls · 3mo agoRegulatoryNegative↗ source
  • AstraZeneca and Bristol Myers Squibb reportedly in talks on a mega merger
    AstraZeneca is said to be discussing a possible merger with Bristol Myers Squibb, according to a Financial Times report published on Sunday. The combination would rank among the largest consolidat…
    Endpoints · 3mo agoDealNeutral↗ source
  • Alnylam’s stock continues to fall as weekly roundup highlights Q2 earnings across biopharma
    The August 1 edition of Endpoints Weekly opens with a look at the latest biopharma earnings season. Alnylam Therapeutics is highlighted for a continued decline in its share price, reflecting ongoi…
    Endpoints · 3mo agoEarningsNegative↗ source
  • Novo Nordisk's heart drug ziltivekimab fails Phase 3 trial, raising doubts on inflammation-targeted therapies
    Novo Nordisk announced that its experimental cardiovascular drug ziltivekimab did not meet the primary endpoint in a Phase 3 study. The trial was designed to see if the drug could lower the inciden…
    BioPharma Dive · 3mo agoNegative readoutNegative↗ source
  • Novo Nordisk's late-stage anti-inflammatory heart drug fails Phase 3 trial
    Novo Nordisk announced that its experimental anti-inflammatory compound designed to target cardiovascular inflammation did not meet its primary endpoint in a Phase 3 trial. The study was intended…
    Endpoints · 3mo agoNegative readoutNegative↗ source
  • Resilience and Eli Lilly commit $750 million to expand Cincinnati GLP-1 injectable production
    Resilience and Eli Lilly announced a joint $750 million investment to expand drug manufacturing capacity in Cincinnati. The expansion will add at least 400 jobs and increase Resilience's workforce…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • AbbVie says Skyrizi maintains strong sales momentum as competition rises
    AbbVie highlighted that its immunology drug Skyrizi continues to generate robust sales despite increasing competition in the market. The company noted that demand for the therapy remains solid and…
    Endpoints · 3mo agoPositive↗ source
  • Pharma groups support revised 340B rebate pilot that permits limited rebate denials
    Health Resources and Services Administration (HRSA) announced details of a revised 340B rebate pilot. The new rules would let drug manufacturers refuse rebates on a limited set of drugs, a shift fr…
    Endpoints · 3mo agoRegulatoryPositive↗ source
  • Sanofi CEO pledges to rebuild trust and expand partnership with Regeneron
    Sanofi's new chief executive, Belén Garijo, told analysts that restoring the relationship with longtime partner Regeneron is a top priority. She said the company wants to be more transparent and to…
    BioPharma Dive · 3mo agoNeutral↗ source
  • Ratio Therapeutics secures $70M Series C for radiopharma trials as Vogenx eyes $67M IPO
    Ratio Therapeutics, a Boston-based biotech, announced a $70 million Series C financing to fund its radiopharmaceutical development program. The round was led by existing backers Duquesne Family Of…
    Endpoints · 3mo agoDealPositive↗ source
  • Karyopharm stock tumbles after Phase 3 Xpovio trial fails in endometrial cancer
    Karyopharm announced that its Phase 3 XPORT-EC-042 study of Xpovio in endometrial cancer did not meet its primary endpoint. The failure represents the company's second unsuccessful attempt to expa…
    Endpoints · 3mo agoNegative readoutNegative↗ source
  • Latigo Biotherapeutics reports non-opioid drug cuts acute pain in Phase 2b trial
    Latigo Biotherapeutics announced that its experimental non-opioid analgesic demonstrated a reduction in acute pain in a Phase 2b clinical trial. The study results suggest the candidate may offer a…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Trump administration proposes 340B rebate pilot for 2027, hospitals push back
    The Health Resources and Services Administration announced a new pilot that would shift some 340B drug discounts to rebate payments starting in 2027. The proposal follows a previous attempt earlie…
    BioPharma Dive · 3mo agoRegulatoryNegative↗ source
  • Moderna delays norovirus vaccine readout, cites insufficient infections
    Moderna announced that its norovirus vaccine trial will not yield efficacy data this season because infection rates were lower than expected. The company said it will open an additional trial coho…
    Endpoints · 3mo agoNegative readoutNeutral↗ source
  • Apnimed secures $192 million IPO to fund sleep-apnea drug program targeting 2027 launch
    Apnimed, a biotech focused on sleep apnea, announced it raised $192 million through an initial public offering. The capital will be used to advance its lead drug candidate, with plans to begin a l…
    Endpoints · 3mo agoDealPositive↗ source
  • Ionis veteran scientist Frank Bennett to retire in 2027 as Recursion appoints its first AI chief
    Ionis announced that Frank Bennett, who joined the company as a founding scientist in 1989 and later became chief scientific officer, will retire in February 2027 after a 37-year career. Bennett’s…
    Endpoints · 3mo agoNeutral↗ source
  • Lidl US expands recall of Eridanous shortbread cookies over undeclared wheat, soy, milk, egg and coconut allergens
    Lidl US announced it is widening a recall that began on July 24, 2026 to cover all units of its Eridanous Shortbread Cookies that feature foreign-language packaging. The affected items include the…
    fda recalls · 3mo agoRegulatoryNeutral↗ source